learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 26 resultslearn GT20029
research compound made to degrade androgen receptors in scalp
learn Overview
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Stemoxydine
chemical from L'Oreal that encourages hair to enter growth phase
Research
5 / 1000+ resultsresearch A Phase II Trial of Retinoids on Lupus Nephritis in a Single Center
Retinoids may help treat lupus nephritis and reduce steroid use.
research Multicentric Parallel Phase II Trial of the Polo-Like Kinase 1 Inhibitor BI 2536 in Patients With Advanced Head and Neck Cancer, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, and Melanoma. The First Protocol of the European Organization for Research and Treatment of Cancer Network of Core Institutes
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Discussion of 'A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III' by Andrew G. Chapple and Peter F. Thall
The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
research Safety and Efficacy of Tavaborole (AN2690), a Novel Boron-Based Molecule, in Three Phase II Trials for the Topical Treatment of Toenail Onychomycosis
Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
research A Prospective Open Labelled Phase-II Non-Randomized Clinical Trial on Karunjchirakam Chooranam for Poly Cystic Ovarian Syndrome
Karunjchirakam Chooranam significantly improved symptoms in most PCOS cases.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community How far along is Kintor in its Phase II U.S. trials for pyrilutamide?
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.